{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T16:28:17Z","timestamp":1788884897684,"version":"build-2803163510"},"reference-count":116,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T00:00:00Z","timestamp":1671667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Italian Ministry of University and Research (MIUR)\u2014Department of Excellence project PREMIA"},{"name":"A. De Gasperis Cardiology and Cardiac Surgery Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Atherosclerosis is a chronic and progressive inflammatory process beginning early in life with late clinical manifestation. This slow pathological trend underlines the importance to early identify high-risk patients and to treat intensively risk factors to prevent the onset and\/or the progression of atherosclerotic lesions. In addition to the common Cardiovascular (CV) risk factors, new markers able to increase the risk of CV disease have been identified. Among them, high levels of Lipoprotein(a)\u2014Lp(a)\u2014lead to very high risk of future CV diseases; this relationship has been well demonstrated in epidemiological, mendelian randomization and genome-wide association studies as well as in meta-analyses. Recently, new aspects have been identified, such as its association with aortic stenosis. Although till recent years it has been considered an unmodifiable risk factor, specific drugs have been developed with a strong efficacy in reducing the circulating levels of Lp(a) and their capacity to reduce subsequent CV events is under testing in ongoing trials. In this paper we will review all these aspects: from the synthesis, clearance and measurement of Lp(a), through the findings that examine its association with CV diseases and aortic stenosis to the new therapeutic options that will be available in the next years.<\/jats:p>","DOI":"10.3390\/ijms24010170","type":"journal-article","created":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T02:06:14Z","timestamp":1671674774000},"page":"170","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Lipoprotein(a): Cardiovascular Disease, Aortic Stenosis and New Therapeutic Option"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2612-6264","authenticated-orcid":false,"given":"Alessandro","family":"Maloberti","sequence":"first","affiliation":[{"name":"Cardiology 4, Cardio Center A. De Gasperis, ASST GOM Niguarda, 20162 Milan, Italy"},{"name":"School of Medicine and Surgery, Milano-Bicocca University, 20126 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saverio","family":"Fabbri","sequence":"additional","affiliation":[{"name":"School of Medicine and Surgery, Milano-Bicocca University, 20126 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Colombo","sequence":"additional","affiliation":[{"name":"School of Medicine and Surgery, Milano-Bicocca University, 20126 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Gualini","sequence":"additional","affiliation":[{"name":"School of Medicine and Surgery, Milano-Bicocca University, 20126 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Monticelli","sequence":"additional","affiliation":[{"name":"School of Medicine and Surgery, Milano-Bicocca University, 20126 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Daus","sequence":"additional","affiliation":[{"name":"School of Medicine and Surgery, Milano-Bicocca University, 20126 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4303-5049","authenticated-orcid":false,"given":"Andrea","family":"Busti","sequence":"additional","affiliation":[{"name":"School of Medicine and Surgery, Milano-Bicocca University, 20126 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Galasso","sequence":"additional","affiliation":[{"name":"School of Medicine and Surgery, Milano-Bicocca University, 20126 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"De Censi","sequence":"additional","affiliation":[{"name":"School of Medicine and Surgery, Milano-Bicocca University, 20126 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Algeri","sequence":"additional","affiliation":[{"name":"Cardiology 4, Cardio Center A. De Gasperis, ASST GOM Niguarda, 20162 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piera Angelica","family":"Merlini","sequence":"additional","affiliation":[{"name":"Cardiology 4, Cardio Center A. De Gasperis, ASST GOM Niguarda, 20162 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Giannattasio","sequence":"additional","affiliation":[{"name":"Cardiology 4, Cardio Center A. De Gasperis, ASST GOM Niguarda, 20162 Milan, Italy"},{"name":"School of Medicine and Surgery, Milano-Bicocca University, 20126 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/S0140-6736(18)32203-7","article-title":"Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980\u20132017: A systematic analysis for the Global Burden of Disease Study 2017","volume":"392","author":"Roth","year":"2018","journal-title":"Lancet"},{"key":"ref_2","unstructured":"(2021). Cardiovascular disease burden: Italian and global perspectives. Minerva Cardioangiol., 69, 231\u2013240."},{"key":"ref_3","first-page":"1","article-title":"Mortality in the United States, 2018","volume":"355","author":"Xu","year":"2020","journal-title":"NCHS Data Brief"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1161\/ATVBAHA.120.315291","article-title":"Lp(a) (Lipoprotein[a]) Concentrations and Incident Atherosclerotic Cardiovascular Disease New Insights from a Large National Biobank","volume":"41","author":"Patel","year":"2021","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.atherosclerosis.2015.08.021","article-title":"Lipoprotein (a) as a risk factor for ischemic stroke: A meta-analysis","volume":"242","author":"Nave","year":"2015","journal-title":"Atherosclerosis"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jacc.2019.03.524","article-title":"Elevated Lipoprotein(a) and Risk of Ischemic Stroke","volume":"74","author":"Langsted","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.jacc.2012.12.023","article-title":"Extreme Lipoprotein(a) Levels and Improved Cardiovascular Risk Prediction","volume":"61","author":"Kamstrup","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1161\/CIRCULATIONAHA.120.045826","article-title":"Lipoprotein(a) in Alzheimer, Atherosclerotic, Cerebrovascular, Thrombotic, and Valvular Disease","volume":"141","author":"Larsson","year":"2020","journal-title":"Circulation"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"The CARDIoGRAMplusC4D Consortium, Deloukas, P., Kanoni, S., Willenborg, C., Farrall, M., Assimes, T.L., Thompson, J.R., Ingelsson, E., Saleheen, D., and Erdmann, J. (2013). Large-scale association analysis identifies new risk loci for coronary artery disease. Nat. Genet., 45, 25\u201333.","DOI":"10.1038\/ng.2480"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_11","first-page":"E48","article-title":"Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement from the American Heart Association","volume":"42","author":"Ginsberg","year":"2022","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2459\/JCM.0000000000001077","article-title":"Lipoprotein(a): A genetic marker for cardiovascular disease and target for emerging therapies","volume":"22","author":"Cesaro","year":"2021","journal-title":"J. Cardiovasc. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1177\/2047487319884380","article-title":"Lipoprotein (a) is an independent predictor of cardiovascular events in Mediterranean women (Progetto Atena)","volume":"27","author":"Gentile","year":"2020","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s11739-019-02082-8","article-title":"Impact of lipoprotein(a) levels on recurrent cardiovascular events in patients with premature coronary artery disease","volume":"14","author":"Gragnano","year":"2019","journal-title":"Intern. Emerg. Med."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"von Eckardstein, A., and Binder, C.J. (2022). Lipoprotein(a) in Prevention and Treatment of Atherosclerosis: Improving State-of-the-Art Management and Search for Novel Targets, Springer International Publishing.","DOI":"10.1007\/978-3-030-86076-9"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3491764","DOI":"10.1155\/2020\/3491764","article-title":"Lipoprotein(a) the Insurgent: A New Insight into the Structure, Function, Metabolism, Pathogenicity, and Medications Affecting Lipoprotein(a) Molecule","volume":"2020","author":"Jawi","year":"2020","journal-title":"J. Lipids"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/BF02533209","article-title":"Immunochemical quantification of human plasma Lp(a) lipoprotein","volume":"9","author":"Albers","year":"1974","journal-title":"Lipids"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/hmg\/2.4.361","article-title":"The apolipoprotein(a) kringle IV repeats which differ from the major repeat kringle are present in variably-sized isoforms","volume":"2","author":"Wittekoek","year":"1993","journal-title":"Hum. Mol. Genet."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1194\/jlr.M040733","article-title":"Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a)","volume":"54","author":"Leibundgut","year":"2013","journal-title":"J. Lipid Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.amjcard.2020.03.043","article-title":"Lipoprotein (a): An Update on a Marker of Residual Risk and Associated Clinical Manifestations","volume":"126","author":"Shah","year":"2020","journal-title":"Am. J. Cardiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"28716","DOI":"10.1016\/S0021-9258(19)61964-2","article-title":"Cell surface assembly of lipoprotein(a) in primary cultures of baboon hepatocytes","volume":"269","author":"White","year":"1994","journal-title":"J. Biol. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Iannuzzo, G., Tripaldella, M., Mallardo, V., Morgillo, M., Vitelli, N., Iannuzzi, A., Aliberti, E., Giallauria, F., Tramontano, A., and Carluccio, R. (2021). Lipoprotein(a) Where Do We Stand? From the Physiopathology to Innovative Terapy. Biomedicines, 9.","DOI":"10.3390\/biomedicines9070838"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1194\/jlr.M800515-JLR200","article-title":"Genome-wide association study of plasma lipoprotein(a) levels identifies multiple genes on chromosome 6q","volume":"50","author":"Ober","year":"2009","journal-title":"J. Lipid Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/jhg.2015.107","article-title":"Genome- and exome-wide association study of serum lipoprotein (a) in the Jackson Heart Study","volume":"60","author":"Li","year":"2015","journal-title":"J. Hum. Genet."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1194\/jlr.M076232","article-title":"A genome-wide association meta-analysis on lipoprotein (a) concentrations adjusted for apolipoprotein (a) isoforms","volume":"58","author":"Mack","year":"2017","journal-title":"J. Lipid Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1194\/jlr.M094540","article-title":"Nonsynonymous SNPs in LPA homologous to plasminogen deficiency mutants represent novel null apo(a) alleles","volume":"61","author":"Morgan","year":"2020","journal-title":"J. Lipid Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"5957","DOI":"10.1016\/S0021-9258(18)83643-2","article-title":"Rhesus Monkey Apolipoprotein(a). Sequence, evolution, and sites of synthesis","volume":"264","author":"Tomlinson","year":"1989","journal-title":"J. Biol. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1172\/JCI113849","article-title":"Changes of genetic apolipoprotein phenotypes caused by liver transplantation. Implications for apolipoprotein synthesis","volume":"83","author":"Kraft","year":"1989","journal-title":"J. Clin. Investig."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1194\/jlr.M500249-JLR200","article-title":"Lipoprotein [a] is cleared from the plasma primarily by the liver in a process mediated by apolipoprotein [a]","volume":"46","author":"Cain","year":"2005","journal-title":"J. Lipid Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0022-2275(20)37150-9","article-title":"Renovascular arteriovenous differences in Lp[a] plasma concentrations suggest removal of Lp[a] from the renal circulation","volume":"38","author":"Kronenberg","year":"1997","journal-title":"J. Lipid Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1172\/JCI117292","article-title":"The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate","volume":"93","author":"Rader","year":"1994","journal-title":"J. Clin. Investig."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1194\/jlr.M029769","article-title":"Nicotinic acid inhibits hepatic APOA gene expression: Studies in humans and in transgenic mice","volume":"53","author":"Chennamsetty","year":"2012","journal-title":"J. Lipid Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1172\/JCI119055","article-title":"Kringle-containing fragments of apolipoprotein(a) circulate in human plasma and are excreted into the urine","volume":"98","author":"Mooser","year":"1996","journal-title":"J. Clin. Investig."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/sj.ki.5002131","article-title":"In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients","volume":"71","author":"Frischmann","year":"2007","journal-title":"Kidney Int."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.pathol.2018.11.003","article-title":"Lipoprotein(a) catabolism: A case of multiple receptors","volume":"51","author":"McCormick","year":"2019","journal-title":"Pathology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1097\/HCO.0000000000000661","article-title":"Current and future role of lipoprotein(a) in preventive cardiology","volume":"34","author":"Berman","year":"2019","journal-title":"Curr. Opin. Cardiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0022-2275(20)41683-9","article-title":"Radioimmunoassay of human plasma Lp(a) lipoprotein","volume":"18","author":"Albers","year":"1977","journal-title":"J. Lipid Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"304","DOI":"10.5312\/wjo.v5.i3.304","article-title":"Inflammation, lipid metabolism and cardiovascular risk in rheumatoid arthritis: A qualitative relationship?","volume":"5","author":"Corbella","year":"2014","journal-title":"World J. Orthop."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.jacl.2019.06.011","article-title":"Individuals with familial hypercholesterolemia and cardiovascular events have higher circulating Lp(a) levels","volume":"13","author":"Pavanello","year":"2019","journal-title":"J. Clin. Lipidol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/clinchem\/41.2.246","article-title":"Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein (a)","volume":"41","author":"Marcovina","year":"1995","journal-title":"Clin. Chem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/clinchem\/hvaa324","article-title":"Development of an LC-MS\/MS Proposed Candidate Reference Method for the Standardization of Analytical Methods to Measure Lipoprotein(a)","volume":"67","author":"Marcovina","year":"2021","journal-title":"Clin. Chem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1093\/clinchem\/46.12.1956","article-title":"Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein (a)","volume":"46","author":"Marcovina","year":"2000","journal-title":"Clin. Chem."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.jacl.2018.07.003","article-title":"Relationship of lipoprotein(a) molar concentrations and mass according to lipoprotein(a) thresholds and apolipoprotein(a) isoform size","volume":"12","author":"Tsimikas","year":"2018","journal-title":"J. Clin. Lipidol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11789-019-00093-5","article-title":"Prediction of cardiovascular risk by Lp(a) concentrations or genetic variants within the LPA gene region","volume":"14","author":"Kronenberg","year":"2019","journal-title":"Clin. Res. Cardiol. Suppl."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1373\/clinchem.2016.258897","article-title":"Fasting Is Not Routinely Required for Determination of a Lipid Profile: Clinical and Laboratory Implications Including Flagging at Desirable Concentration Cutpoints\u2014A Joint Consensus Statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine","volume":"62","author":"Nordestgaard","year":"2016","journal-title":"Clin. Chem."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Emerging Risk Factors Collaboration (2009). Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality. JAMA J. Am. Med. Assoc., 302, 412\u2013423.","DOI":"10.1001\/jama.2009.1063"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jacl.2017.10.024","article-title":"Temporal variability in lipoprotein(a) levels in patients enrolled in the placebo arms of IONIS-APO(a)Rx and IONIS-APO(a)-LRx antisense oligonucleotide clinical trials","volume":"12","author":"Marcovina","year":"2018","journal-title":"J. Clin. Lipidol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS Guidelines for the Management of Dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1161\/ATVBAHA.114.304785","article-title":"Race is a key variable in assigning lipoprotein(a) cutoff values for coronary heart disease risk assessment: The Multi-Ethnic Study of Atherosclerosis","volume":"35","author":"Guan","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s11886-019-1182-0","article-title":"Lp(a): Addressing a Target for Cardiovascular Disease Prevention","volume":"21","author":"Vasquez","year":"2019","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0021-9150(81)90103-9","article-title":"Lipoprotein Lp(a) and the risk for myocardial infarction","volume":"38","author":"Kostner","year":"1981","journal-title":"Atherosclerosis"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-2796.2012.02592.x","article-title":"Lipoprotein(a): Resurrected by genetics","volume":"273","author":"Kronenberg","year":"2013","journal-title":"J. Intern. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jacl.2019.04.010","article-title":"Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association","volume":"13","author":"Wilson","year":"2019","journal-title":"J. Clin. Lipidol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: A European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/clinchem\/hvaa247","article-title":"Lipoprotein(a) and Cardiovascular Disease","volume":"67","author":"Kamstrup","year":"2021","journal-title":"Clin. Chem."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1161\/01.STR.0000078370.12085.02","article-title":"Pentanucleotide TTTTA Repeat Polymorphism of Apolipoprotein(a) Gene and Plasma Lipoprotein(a) Are Associated with Ischemic and Hemorrhagic Stroke in Chinese: A multicenter case-control study in China","volume":"34","author":"Sun","year":"2003","journal-title":"Stroke"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1373\/clinchem.2007.088013","article-title":"Increased Serum Lipoprotein(a) Concentrations and Low Molecular Weight Phenotypes of Apolipoprotein(a) Are Associated with Symptomatic Peripheral Arterial Disease","volume":"53","author":"Dieplinger","year":"2007","journal-title":"Clin. Chem."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.atherosclerosis.2021.11.019","article-title":"High lipoprotein(a) is associated with major adverse limb events after femoral artery endarterectomy","volume":"349","author":"Verwer","year":"2022","journal-title":"Atherosclerosis"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3400\/avd.oa.22-00046","article-title":"Lipoprotein(a) is a Promising Residual Risk Factor for Long-Term Clinical Prognosis in Peripheral Arterial Disease","volume":"15","author":"Sakata","year":"2022","journal-title":"Ann. Vasc. Dis."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Norby, F.L., Eryd, S.A., Niemeijer, M.N., Rose, L.M., Smith, A.V., Yin, X., Agarwal, S.K., Arking, D.E., Chasman, D.L., and Chen, L. (2016). Association of Lipid-Related Genetic Variants with the Incidence of Atrial Fibrillation: The AFGen Consortium. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0151932"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e008401","DOI":"10.1161\/CIRCEP.120.008401","article-title":"Lp(a) (Lipoprotein [a]) and Risk for Incident Atrial Fibrillation: Multi-Ethnic Study of Atherosclerosis","volume":"13","author":"Garg","year":"2020","journal-title":"Circ. Arrhythm. Electrophysiol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12944-021-01482-0","article-title":"Association of Lipoprotein (a) variants with risk of cardiovascular disease: A Mendelian randomization study","volume":"20","author":"Xia","year":"2021","journal-title":"Lipids Health Dis."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s12944-022-01728-5","article-title":"Low lipoprotein(a) concentration is associated with atrial fibrillation: A large retrospective cohort study","volume":"21","author":"Tao","year":"2022","journal-title":"Lipids Health Dis."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/j.jacc.2022.02.018","article-title":"Elevated Lipoprotein(a) and Risk of Atrial Fibrillation: An Observational and Mendelian Randomization Study","volume":"79","author":"Chong","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/j.1399-0004.1997.tb04343.x","article-title":"Lipoprotein(a) in plasma, arterial wall, and thrombus from patients with aortic aneurysm","volume":"52","author":"Papagrigorakis","year":"1997","journal-title":"Clin. Genet."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1161\/ATVBAHA.112.251306","article-title":"Mechanisms of Lipoprotein(a) Pathogenicity","volume":"32","author":"Spence","year":"2012","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1126\/science.8503012","article-title":"Proliferation of Human Smooth Muscle Cells Promoted by Lipoprotein(a)","volume":"260","author":"Grainger","year":"1993","journal-title":"Science"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1161\/ATVBAHA.108.179697","article-title":"History of discovery: Oxidized Low-Density Lipoprotein and Atherosclerosis","volume":"30","author":"Steinberg","year":"2010","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1194\/jlr.M060210","article-title":"Mechanistic insights into Lp(a)-induced IL-8 expression: A role for oxidized phospholipid modification of apo(a)","volume":"56","author":"Scipione","year":"2015","journal-title":"J. Lipid Res."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Lim, T.T., W\u00fcrtz, P., Havulinna, A.S., Palta, P., Tukiainen, T., Rehnstr\u00f6m, K., Esko, T., M\u00e4gi, R., Inouye, M., and Lappalainen, T. (2014). Distribution and Medical Impact of Loss-of-Function Variants in the Finnish Founder Population. PLoS Genet., 10.","DOI":"10.1371\/journal.pgen.1004494"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1161\/01.CIR.96.8.2514","article-title":"Apolipoprotein(a) Induces Monocyte Chemotactic Activity in Human Vascular Endothelial Cells","volume":"96","author":"Poon","year":"1997","journal-title":"Circulation"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa1109034","article-title":"Genetic Associations with Valvular Calcification and Aortic Stenosis","volume":"368","author":"Thanassoulis","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","article-title":"Elevated Lipoprotein(a) and Risk of Aortic Valve Stenosis in the General Population","volume":"63","author":"Kamstrup","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.jacc.2015.07.020","article-title":"Oxidized Phospholipids, Lipoprotein(a), and Progression of Calcific Aortic Valve Stenosis","volume":"66","author":"Capoulade","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1093\/eurheartj\/ehac377","article-title":"Lipoprotein(a) is associated with the onset but not the progression of aortic valve calcification","volume":"43","author":"Kaiser","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1161\/ATVBAHA.107.145805","article-title":"Oxidized Phospholipids, Lipoprotein(a), Lipoprotein-Associated Phospholipase A2 Activity, and 10-Year Cardiovascular Outcomes: Prospective results from the bruneck study","volume":"27","author":"Kiechl","year":"2007","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1161\/01.CIR.90.2.844","article-title":"Characterization of the early lesion of \u2018degenerative\u2019 valvular aortic stenosis. Histological and immunohistochemical studies","volume":"90","author":"Otto","year":"1994","journal-title":"Circulation"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11883-019-0803-9","article-title":"Looking at Lp(a) and Related Cardiovascular Risk: From Scientific Evidence and Clinical Practice","volume":"21","author":"Stulnig","year":"2019","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1093\/eurheartj\/ehx653","article-title":"Calcific aortic valve stenosis: Hard disease in the heart","volume":"39","author":"Peeters","year":"2017","journal-title":"Eur. Heart J."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Schnitzler, J.G., Ali, L., Groenen, A.G., Kaiser, Y., and Kroon, J. (2019). Lipoprotein(a) as Orchestrator of Calcific Aortic Valve Stenosis. Biomolecules, 9.","DOI":"10.3390\/biom9120760"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1359\/jbmr.2003.18.10.1842","article-title":"BMP-2 Controls Alkaline Phosphatase Expression and Osteoblast Mineralization by a Wnt Autocrine Loop","volume":"18","author":"Rawadi","year":"2003","journal-title":"J. Bone Miner. Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1161\/CIRCULATIONAHA.116.020838","article-title":"Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans","volume":"134","author":"Bekkering","year":"2016","journal-title":"Circulation"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/eurheartj\/ehab395","article-title":"2021 ESC\/EACTS Guidelines for the management of valvular heart disease","volume":"43","author":"Vahanian","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1001\/jamacardio.2020.0728","article-title":"An Exploratory Analysis of Proprotein Convertase Subtilisin\/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial","volume":"5","author":"Bergmark","year":"2020","journal-title":"JAMA Cardiol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/ehjci\/jev338","article-title":"Lipoprotein(a) is a risk factor for aortic and mitral valvular stenosis in peripheral arterial disease","volume":"17","author":"Hojo","year":"2016","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.atherosclerosis.2021.11.029","article-title":"Elevated lipoprotein(a) in mitral and aortic valve calcification and disease: The Copenhagen General Population Study","volume":"349","author":"Kaltoft","year":"2022","journal-title":"Atherosclerosis"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jcct.2020.06.002","article-title":"Lipoprotein (a) and risk for calcification of the coronary arteries, mitral valve, and thoracic aorta: The Multi-Ethnic Study of Atherosclerosis","volume":"15","author":"Garg","year":"2020","journal-title":"J. Cardiovasc. Comput. Tomogr."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.jacc.2021.12.016","article-title":"Managing Atherosclerotic Cardiovascular Risk in Young Adults: JACC State-of-the-Art Review","volume":"79","author":"Stone","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1001\/jamacardio.2019.1041","article-title":"For the Lp(a)-GWAS-Consortium Estimation of the Required Lipoprotein(a)-Lowering Therapeutic Effect Size for Reduction in Coronary Heart Disease Outcomes: A Mendelian Randomization Analysis","volume":"4","author":"Lamina","year":"2019","journal-title":"JAMA Cardiol."},{"key":"ref_92","first-page":"1784","article-title":"Extreme cardiovascular risk\u2014Do we need a new risk category?","volume":"43","author":"Penson","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.jacc.2014.01.006","article-title":"Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145): A pooled analysis of more than 1300 patients in 4 phase II trials","volume":"63","author":"Raal","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1194\/jlr.R051904","article-title":"Lipoprotein (a): Impact by ethnicity and environmental and medical conditions","volume":"57","author":"Enkhmaa","year":"2016","journal-title":"J. Lipid Res."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.atherosclerosis.2019.07.001","article-title":"Statin treatment increases lipoprotein(a) levels in subjects with low molecular weight apolipoprotein(a) phenotype","volume":"289","author":"Yahya","year":"2019","journal-title":"Atherosclerosis"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: Current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur. Heart J."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/j.metabol.2016.08.007","article-title":"Effect of extended-release niacin on plasma lipoprotein(a) levels: A systematic review and meta-analysis of randomized placebo-controlled trials","volume":"65","author":"Sahebkar","year":"2016","journal-title":"Metabolism"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"(2011). The AIM-HIGH Investigators Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy. N. Engl. J. Med., 365, 2255\u20132267.","DOI":"10.1056\/NEJMoa1107579"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"(2014). The HPS2-THRIVE Collaborative Group Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients. N. Engl. J. Med., 371, 203\u2013212.","DOI":"10.1056\/NEJMoa1300955"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk insights from the FOURIER trial","volume":"139","author":"Fazio","year":"2019","journal-title":"Circulation"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","article-title":"Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome","volume":"75","author":"Bittner","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia","volume":"382","author":"Raal","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.jacc.2013.07.081","article-title":"Mipomersen, an Apolipoprotein B Synthesis Inhibitor, Reduces Atherogenic Lipoproteins in Patients with Severe Hypercholesterolemia at High Cardiovascular Risk: A randomized, double-blind, placebo-controlled trial","volume":"62","author":"Thomas","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1194\/jlr.R056549","article-title":"Thematic review series: Lipoprotein (a): Coming of age at last Lipoprotein apheresis to treat elevated lipoprotein (a)","volume":"57","author":"Waldmann","year":"2016","journal-title":"J. Lipid Res."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.jacl.2020.05.002","article-title":"Lipoprotein(a) concentration, genetic variants, apo(a) isoform size, and cellular cholesterol efflux in patients with elevated Lp(a) and coronary heart disease submitted or not to lipoprotein apheresis: An Italian case-control multicenter study on Lp(a)","volume":"14","author":"Stefanutti","year":"2020","journal-title":"J. Clin. Lipidol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jacl.2011.04.003","article-title":"Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients","volume":"5","author":"Goldberg","year":"2011","journal-title":"J. Clin. Lipidol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"e003294","DOI":"10.1161\/JAHA.116.003294","article-title":"Systematic Review of Low-Density Lipoprotein Cholesterol Apheresis for the Treatment of Familial Hypercholesterolemia","volume":"5","author":"Wang","year":"2016","journal-title":"J. Am. Heart Assoc."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.5551\/jat.14621","article-title":"Guidelines for the Management of Familial Hypercholesterolemia","volume":"19","author":"Arai","year":"2012","journal-title":"J. Atheroscler. Thromb."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11789-012-0046-6","article-title":"Current view: Indications for extracorporeal lipid apheresis treatment","volume":"7","author":"Schettler","year":"2012","journal-title":"Clin. Res. Cardiol. Suppl."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"104413","DOI":"10.1016\/j.phrs.2019.104413","article-title":"A new dawn for managing dyslipidemias: The era of rna-based therapies","volume":"150","author":"Macchi","year":"2019","journal-title":"Pharmacol. Res."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","article-title":"Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): Two randomised, double-blind, placebo-controlled, dose-ranging trials","volume":"388","author":"Viney","year":"2016","journal-title":"Lancet"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) Reduction in Persons with Cardiovascular Disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"New Engl. J. Med."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.atherosclerosis.2021.03.036","article-title":"Prevalence and influence of LPA gene variants and isoform size on the Lp(a)-lowering effect of pelacarsen","volume":"324","author":"Xia","year":"2021","journal-title":"Atherosclerosis"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41591-021-01634-w","article-title":"Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)","volume":"28","author":"Koren","year":"2022","journal-title":"Nat. Med."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ahj.2022.05.004","article-title":"Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN(a) reduction-DOSE finding study (OCEAN(a)-DOSE)","volume":"251","author":"Knusel","year":"2022","journal-title":"Am. Heart J."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2022.5050","article-title":"Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals with Elevated Plasma Lipoprotein(a) Levels","volume":"327","author":"Nissen","year":"2022","journal-title":"JAMA"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/1\/170\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:47:31Z","timestamp":1760147251000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/1\/170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,22]]},"references-count":116,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["ijms24010170"],"URL":"https:\/\/doi.org\/10.3390\/ijms24010170","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,22]]}}}